Pub. Date : 2009
PMID : 19929036
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In subgroup analyses, valsartan lost dominance in patients in NYHA II, and in those receiving beta-adrenoceptor antagonists or ACE inhibitors; the mean incremental cost-utility ratio for these groups was 21 240, 129 200, and 36 500 and U20AC;/QALY, respectively. | Valsartan | angiotensin I converting enzyme | Homo sapiens |
| 2 | There are relevant differences among various patient subgroups, and valsartan is expected to be good value for money particularly in the treatment of the most severe and less intensively treated (no ACE inhibitors, no beta-adrenoceptor antagonist) heart failure patients. | Valsartan | angiotensin I converting enzyme | Homo sapiens |